CA2321951A1 - Dietary control of arachidonic acid metabolism - Google Patents

Dietary control of arachidonic acid metabolism Download PDF

Info

Publication number
CA2321951A1
CA2321951A1 CA002321951A CA2321951A CA2321951A1 CA 2321951 A1 CA2321951 A1 CA 2321951A1 CA 002321951 A CA002321951 A CA 002321951A CA 2321951 A CA2321951 A CA 2321951A CA 2321951 A1 CA2321951 A1 CA 2321951A1
Authority
CA
Canada
Prior art keywords
composition
acid
flavoring agent
unsaturated fatty
delta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002321951A
Other languages
French (fr)
Other versions
CA2321951C (en
Inventor
Floyd H. Chilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wake Forest University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2321951A1 publication Critical patent/CA2321951A1/en
Application granted granted Critical
Publication of CA2321951C publication Critical patent/CA2321951C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of .DELTA.5 desaturase, and stearidonic acid or .omega.-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

Claims (35)

1. A composition for diminishing symptoms of inflammatory disorders, said composition composing .gamma.-linolenic acid or dihomogammalinolenic acid, 2 .DELTA.5 desaturase inhibitor, and a competitive inhibitor of arachidonic acid metabolism.
2. The composition of claim 1, wherein the .gamma.-linolenic acid or dihomogammalinolenic acid, the .DELTA.5 desaturase inhibitor, and the competitive inhibitor are from around 80% to about 95%
pure unsaturated fatty acids.
3. The composition of claim 1, wherein the .DELTA.5 desaturase inhibitor is eicosapentaenoic acid, sesamin, episesamin, sesaminol, sesamolin, curcumin, heneicosapentaenoic acid, docosahexaenoic acid, alkyl gallate, propyl gallate, or p-isopentoxyaniline.
4. The composition of claim 2, wherein the .DELTA.5 desaturase inhibitor is a free fatty acid, a fatty acyl ester, a triglyceride, an ethyl ester, a phospholipid, a steryl ester, a sphingolipid, or a combination of these.
5. The composition of claim 1, wherein the competitive inhibitor of arachidonic acid metabolism is .omega.-3 arachidonic acid or stearidonic acid.
6. The composition of claim 1, wherein the composition is a flavored drink.
7. The composition of claim 1, wherein the composition is a powder.
8. The composition of claim 1, further defined as comprising water, corn syrup, maltodextrin, sodium caseinate, calcium caseinate. soy protein, magnesium chloride, potassium citrate, calcium phosphate tribasic, or soy lecithin.
9. The composition of claim 1, wherein said composition is contained in an essentially oxygen-free air-tight container.
10. The composition of claim 9, wherein said container is sealed in an oxidatively inert gas environment.
11. The composition of claim 10, wherein said container is a can.
12. The composition of claim 1 further comprising a flavoring agent.
13. The composition of claim 12, wherein said flavoring agent is a fruit flavoring agent or a fruit juice.
14. The composition of claim 12, wherein said flavoring agent is a vanilla, chocolate, eggnog, or berry flavoring agent.
15. The composition of claim 1, further comprising an antioxidant.
16. The composition of claim 15, wherein said antioxidant is beta-carotene, vitamin E, vitamin C, selenium, alpha tocopherol, or taurine.
17. The composition of claim 1, further comprising an emulsifying agent.
18. A milk based drink for treatment of inflammatory disorders comprising an unsaturated fatty acid portion, wherein said unsaturated fatty acid portion consists of .gamma.-linolenic acid, a .DELTA.5 desaturase inhibitor, and stearidonic acid.
19. The drink of claim 18, wherein said .DELTA.5 desaturase inhibitor is eicosapentaenoic acid, sesamin, episesamin, sesaminol, sesamolin, curcumin, heneicosapentaenoic acid, docosahexaenoic acid, alkyl gallate, propyl gallate. or p-isopentoxyaniline.
20. A composition for treatment of an inflammatory disorder comparing .gamma.-linolenic acid, eicosapentaenoic acid, and .omega.-3 arachidonic acid.
21. The composition of claim 20, wherein said disorder is asthma. allergic rhinitis, allergic rhinoconjunctivitis, psoriasis, acute myocardial infarction, glomerulonephritis, Crohn's disease, inflammatory bowel disease, or arthritis.
22. A composition comprising a milk-based liquid comprising an unsaturated fatty acid portion, wherein the unsaturated fatty acid portion consists of 80-95% pure .gamma.-linolenic acid, eicosapentaenoic acid, and stearidonic acid.
23. The composition of claim 22, wherein said unsaturated fatty acid portion comprises at least one unsaturated fatty acid isolated from a transgenic cell engineered to produce said at least one unsaturated fatty acid.
24. The composition of claim 22. wherein the composition is a liquid.
25. The composition of claim 22, wherein the composition is a powder.
26. The composition of claim 22, further defined as comprising water, corn syrup, maltodextrin, sodium caseinate, calcium caseinate, soy protein, magnesium chloride, potassium citrate, calcium phosphate tribasic, or soy lecithin.
27. The composition of claim 22. wherein said composition is contained in an essentially oxygen-free air-tight container.
28. The composition of claim 27, wherein said container is sealed in an oxidatively inert gas environment.
29. The composition of claim 28. wherein said container is a can.
30. The composition of claim 22 further comprising a flavoring agent.
31. The composition of claim 30, wherein said flavoring agent is a fruit flavoring agent or a fruit juice.
32. The composition of claim 30, wherein said flavoring agent is a vanilla, chocolate, eggnog, or berry flavoring agent.
33. The composition of claim 22, further comprising an antioxidant.
34. The composition of claim 33, wherein said antioxidant is beta-carotene, vitamin E, vitamin C, selenium, alpha tocopherol, or taurine.
35. The composition of claim 22, further comprising an emulsifying agent.
CA2321951A 1998-02-23 1999-02-12 Dietary control of arachidonic acid metabolism Expired - Fee Related CA2321951C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/028,256 1998-02-23
US09/028,256 US6107334A (en) 1998-02-23 1998-02-23 Dietary control of arachidonic acid metabolism
PCT/US1999/003120 WO1999042101A1 (en) 1998-02-23 1999-02-12 Dietary control of arachidonic acid metabolism

Publications (2)

Publication Number Publication Date
CA2321951A1 true CA2321951A1 (en) 1999-08-26
CA2321951C CA2321951C (en) 2010-04-27

Family

ID=21842416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2321951A Expired - Fee Related CA2321951C (en) 1998-02-23 1999-02-12 Dietary control of arachidonic acid metabolism

Country Status (9)

Country Link
US (1) US6107334A (en)
EP (1) EP1063987A4 (en)
JP (1) JP2002503690A (en)
KR (1) KR20010041220A (en)
AU (3) AU2676999A (en)
CA (1) CA2321951C (en)
IL (2) IL137928A0 (en)
NZ (1) NZ506618A (en)
WO (1) WO1999042101A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3354581B2 (en) * 1991-09-30 2002-12-09 サントリー株式会社 Method for producing dihomo-γ-linolenic acid and lipid containing the same
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US6506412B2 (en) * 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
US20020145589A1 (en) * 2001-04-06 2002-10-10 Sony Corporation Of Japan User interface for an e-marker
JP4728561B2 (en) * 2001-05-14 2011-07-20 マーテック バイオサイエンシーズ コーポレーション Purification and use of polar lipid-rich fractions containing stearidonic acid and gamma-linolenic acid derived from plant seeds and microorganisms
WO2002092779A2 (en) * 2001-05-17 2002-11-21 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
GB0113348D0 (en) * 2001-06-01 2001-07-25 Mars Uk Ltd Skin diet
BR0308290A (en) * 2002-03-08 2005-01-11 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
WO2003086468A1 (en) * 2002-04-10 2003-10-23 Cargill, Incorporated Aqueous dispersible steryl ester compositions
US8841344B2 (en) * 2002-10-03 2014-09-23 Hill's Pet Nutrition, Inc. Method of using omega-3 fatty acids
US20040208939A1 (en) * 2003-04-18 2004-10-21 Barry Sears Novel dietary compositions to reduce inflammation
ITMI20031311A1 (en) * 2003-06-27 2004-12-28 Indena Spa FORMULATIONS FOR THE TREATMENT OF ARTHROSIC DISORDERS.
KR100693150B1 (en) 2005-04-06 2007-03-13 주식회사 리포젠 A Supplementary Food Composition Comprising Reformed Triglyceride Lipid
CA2609341C (en) * 2005-05-23 2011-10-04 Natural Asa Concentration of fatty acid alkyl esters by enzymatic reactions with glycerol
US20070207223A1 (en) * 2006-03-03 2007-09-06 Dirienzo Maureen A Means for improving cardiovascular health
CA2659272C (en) * 2006-07-28 2015-06-16 Bioriginal Food & Science Corporation Fat containing composition
JP5207341B2 (en) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 Inflammatory cytokine production inhibitor
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008089310A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
IT1392312B1 (en) * 2008-12-16 2012-02-24 Pharmarte S R L FORMULATION FOR VAGINAL ADMINISTRATION BASED ON OMEGA-3 POLYSATURATED FATTY ACIDS AND MAGNESIUM COMPOUNDS.
GB0909643D0 (en) 2009-06-04 2009-07-22 Avexxin As Glomerulonephritis treatment
GB201014633D0 (en) 2010-09-02 2010-10-13 Avexxin As Rheumatoid arthritis treatment
CA2916208A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
KR101744588B1 (en) 2014-12-24 2017-06-09 대상 주식회사 Process for preparing omega-3 unsaturated fatty acid-containing powder
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
US20210392935A1 (en) * 2018-11-30 2021-12-23 Evonik Operations Gmbh Preparation comprising a probiotic strain of the genus bacillus megaterium and a polyunsaturated fatty acid component
CN113549594B (en) * 2021-07-21 2022-09-02 何海萍 Application of asaricin in promoting mesenchymal stem cells to play immunosuppressive role

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444755A (en) * 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
EP0004770B1 (en) * 1978-04-11 1984-06-13 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
EP0179959A1 (en) * 1982-04-20 1986-05-07 Merck Frosst Canada Inc. Conjugates of leukotrienes with proteins
IE54795B1 (en) * 1982-04-29 1990-02-14 Efamol Ltd Pharmaceutical composition
US4560514A (en) * 1984-05-04 1985-12-24 Bengt Samuelsson Inflammatory lipoxin A and anti-anflammatory lipoxin B compounds
US4576758A (en) * 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
GB8425006D0 (en) * 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
WO1990014824A1 (en) * 1988-01-14 1990-12-13 Anders Frithz Use of essential fatty acids for the preparation of a drug for the treatment of eczema
CH676909A5 (en) * 1988-12-23 1991-03-28 Nestle Sa
JP3070611B2 (en) * 1989-03-07 2000-07-31 サントリー株式会社 △ ▲ Top 5 ▼ ―Unsaturated enzyme inhibitor
EP0457950B1 (en) * 1990-05-23 1993-10-20 Societe Des Produits Nestle S.A. Use of stearidonic acid in the treatment of inflammatory disorders
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
DE4238869C2 (en) * 1992-11-18 1994-09-08 Wogepharm Gmbh Agents for the treatment of atopic eczema and other inflammatory skin diseases
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
EP0711503A3 (en) * 1994-11-14 1997-11-26 Scotia Holdings Plc Milk fortified with GLA and/or DGLA
GB9423625D0 (en) * 1994-11-23 1995-01-11 Scotia Holdings Plc Fortified fruit juice
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
CA2240165A1 (en) * 1995-12-11 1997-06-19 Inholtra, Inc. Dietary regimen of nutritional supplements for relief of symptoms of arthritis
JP4151853B2 (en) 1996-10-11 2008-09-17 スカリスタ リミテッド A therapeutic agent containing eicosapentaenoic acid and / or stearidonic acid

Also Published As

Publication number Publication date
KR20010041220A (en) 2001-05-15
IL137928A0 (en) 2001-10-31
EP1063987A1 (en) 2001-01-03
CA2321951C (en) 2010-04-27
WO1999042101A1 (en) 1999-08-26
AU2006203661A1 (en) 2006-09-14
AU2676999A (en) 1999-09-06
IL137928A (en) 2006-08-20
JP2002503690A (en) 2002-02-05
US6107334A (en) 2000-08-22
AU2002314640B2 (en) 2006-06-01
NZ506618A (en) 2003-05-30
AU2002314640A1 (en) 2003-04-10
EP1063987A4 (en) 2005-01-12

Similar Documents

Publication Publication Date Title
CA2321951A1 (en) Dietary control of arachidonic acid metabolism
Horrobin Low prevalences of coronary heart disease (CHD), psoriasis, asthma and rheumatoid arthritis in Eskimos: are they caused by high dietary intake of eicosapentaenoic acid (EPA), a genetic variation of essential fatty acid (EFA) metabolism or a combination of both?
EP0639333B1 (en) Lipid composition for use in food products
US5059622A (en) Method for reducing blood pressure levels in hypertensive persons
US8247449B2 (en) Methods and compositions for the treatment of asthma
EP0713653A1 (en) Fortified fruit juice
EP1088552B1 (en) Compositions containing pinolenic acid and its use a health component
US20020188024A1 (en) Fatty acid-containing emulsion with increased bioavailability
EP0711503A2 (en) Milk fortified with GLA and/or DGLA
CA2129452A1 (en) Nutritional product for pulmonary patients
AU2015321444B2 (en) Fatty acid composition and method for fortifying nutritional products with fatty acids
ATE361066T1 (en) POLYUNSATURATED FATTY ACID NUTRITIONAL SUPPLEMENT
MX2008011351A (en) Stearidonic acid for improving cardiovascular health.
Bhagat et al. State of the art paper Potential role of dietary lipids in the prophylaxis of some clinical conditions
EP2509431B1 (en) Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
JP2006306812A (en) Acidocyte infiltration inhibitor
EP1578214B1 (en) Food composition comprising a satiety enhancing amount of triacylglycerol
JP2006306813A (en) Mast cell increase inhibitor
Ling et al. Early development of essential fatty acid deficiency in rats: fat-free vs. hydrogenated coconut oil diet
Steffens et al. The importance of silver carp and bighead carp as dietetic foodstuffs for prophylaxis and therapy of cardiovascular diseases.
Mitsuyoshi et al. Effects of eicosapentaenoic acid on lipid metabolism in obesity treatment
EP2002729A1 (en) Use of pinolenic acid for lowering cholesterol

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170213